CN Bio Introduces Physiomimix NASH “In-a-Box” Reagent Kit; First Product Within New “In-a-Box’ Range That Harnesses Next-Generation, Human-Relevant Liver-on-a-Chip Technology to Improve Accuracy and Efficiency of NASH Drug Discovery

On April 26, 2022, CN Bio, a leading Organ-on-a-chip (OOC) company that designs and manufactures single- and multi-organ microphysiological systems (MPS), introduced its PhysioMimix™“in-a-box” reagent kit for non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD). Previously, only accessible via its contract research services, CN Bio’s best-in-class NASH in vitro model supports the urgent development of therapeutics to treat this emerging global healthcare priority.